MX2013005989A - Tratamiento de obesidad utilizando administracion no diaria de 6-o-(4-dimetilaminoetoxi)cinamoil fumagilol. - Google Patents
Tratamiento de obesidad utilizando administracion no diaria de 6-o-(4-dimetilaminoetoxi)cinamoil fumagilol.Info
- Publication number
- MX2013005989A MX2013005989A MX2013005989A MX2013005989A MX2013005989A MX 2013005989 A MX2013005989 A MX 2013005989A MX 2013005989 A MX2013005989 A MX 2013005989A MX 2013005989 A MX2013005989 A MX 2013005989A MX 2013005989 A MX2013005989 A MX 2013005989A
- Authority
- MX
- Mexico
- Prior art keywords
- obesity
- daily administration
- dimethylaminoethoxy
- treatment
- cinnamoyl fumagillol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La invención se refiere, en general, a métodos para tratar a un sujeto con sobrepeso u obeso, y al tratamiento de las condiciones relacionadas con sobrepeso u obesidad utilizando administración no diaria de, por ejemplo, un inhibidor de MetAP-2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41769210P | 2010-11-29 | 2010-11-29 | |
US201161500662P | 2011-06-24 | 2011-06-24 | |
PCT/US2011/062413 WO2012075020A1 (en) | 2010-11-29 | 2011-11-29 | Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013005989A true MX2013005989A (es) | 2013-08-21 |
Family
ID=45316099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013005989A MX2013005989A (es) | 2010-11-29 | 2011-11-29 | Tratamiento de obesidad utilizando administracion no diaria de 6-o-(4-dimetilaminoetoxi)cinamoil fumagilol. |
Country Status (10)
Country | Link |
---|---|
US (6) | US9173865B2 (es) |
EP (1) | EP2646016B1 (es) |
JP (1) | JP2013543899A (es) |
KR (1) | KR20140009273A (es) |
CN (1) | CN103379905A (es) |
AU (1) | AU2011336785A1 (es) |
BR (1) | BR112013013411A2 (es) |
CA (1) | CA2819251A1 (es) |
MX (1) | MX2013005989A (es) |
WO (1) | WO2012075020A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2317845A4 (en) * | 2008-07-18 | 2011-11-09 | Zafgen Inc | METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON |
US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
JP5890312B2 (ja) | 2009-10-09 | 2016-03-22 | ザフゲン,インコーポレイテッド | 肥満治療に用いられるスルホン化合物 |
KR101696960B1 (ko) | 2010-01-08 | 2017-01-16 | 자프겐 인크. | 푸마길롤 타입 화합물 및 그의 제조 및 사용 방법 |
US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
KR20130043207A (ko) | 2010-07-22 | 2013-04-29 | 자프겐 인크. | 트리시클릭 화합물 및 이의 제조 및 사용 방법 |
JP2013543899A (ja) | 2010-11-29 | 2013-12-09 | ザフゲン,インコーポレイテッド | 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療 |
WO2012103333A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen Corporation | Tetrazole compounds and methods of making and using same |
JP5876513B2 (ja) | 2011-03-08 | 2016-03-02 | ザフゲン,インコーポレイテッド | オキサスピロ[2.5]オクタン誘導体および類似体 |
AU2012253759B2 (en) | 2011-05-06 | 2016-01-21 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
CN103764641B (zh) | 2011-05-06 | 2016-10-26 | 扎夫根股份有限公司 | 部分饱和的三环化合物及其制备和使用方法 |
CA2835209A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen, Inc. | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
EP2763671A2 (en) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Methods of treating age related disorders |
CA2861390A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
JP2015516426A (ja) | 2012-05-08 | 2015-06-11 | ザフゲン,インコーポレイテッド | MetAP2阻害剤による視床下部性肥満症の治療 |
JP6177888B2 (ja) | 2012-05-09 | 2017-08-09 | ザフゲン,インコーポレイテッド | フマギロール型化合物ならびにその製造および使用方法 |
MX2015005732A (es) | 2012-11-05 | 2015-12-16 | Zafgen Inc | Compuestos tricíclicos y métodos para hacer y utilizar los mismos. |
CN104918928A (zh) | 2012-11-05 | 2015-09-16 | 扎夫根股份有限公司 | 三环化合物及其制备方法和用途 |
EP2968250B1 (en) | 2013-03-14 | 2019-06-19 | Zafgen, Inc. | Methods of treating renal disease and other disorders |
MX371095B (es) * | 2013-04-10 | 2020-01-16 | Syndevrx Inc | Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad. |
CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5164410A (en) | 1988-01-09 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
DE68927904T2 (de) | 1988-09-01 | 1997-09-04 | Takeda Chemical Industries Ltd | Fumagillol-Derivate |
US5180738A (en) | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
EP0387650B1 (en) | 1989-03-06 | 1993-03-31 | Takeda Chemical Industries, Ltd. | 6-epifumagillols, production and use thereof |
US5288722A (en) | 1989-03-06 | 1994-02-22 | Takeda Chemical Industries, Ltd. | 6-amino-6-desoxyfumagillols, production and use thereof |
US6017954A (en) | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
US5290807A (en) | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
EP0415294A3 (en) | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
TW282399B (es) | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
EP0555693B1 (en) | 1992-01-30 | 2001-09-05 | Takeda Chemical Industries, Ltd. | Method of producing highly watersoluble cyclodextrin complex |
EP0602586B1 (en) | 1992-12-16 | 1997-06-04 | Takeda Chemical Industries, Ltd. | Stable pharmaceutical composition of fumagillol derivatives |
JP3260378B2 (ja) | 1995-03-27 | 2002-02-25 | サノフィーサンテラボ | 腸感染に対する薬物の調製のためのフマギロールおよびその誘導体の使用 |
CA2234401A1 (en) | 1995-10-11 | 1997-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Vascular permeation inhibitor |
EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
AU3968597A (en) | 1996-08-02 | 1998-02-25 | Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
US6207704B1 (en) | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
US6306819B1 (en) | 1997-10-31 | 2001-10-23 | Massachusetts Institute Of Technology | Method for regulating size of vascularized normal tissue |
KR100357541B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
JP2000116337A (ja) | 1998-10-09 | 2000-04-25 | Nippon Shokuhin Kako Co Ltd | ペットフード |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
AU782404B2 (en) | 1999-04-28 | 2005-07-28 | Sanofi-Aventis Deutschland Gmbh | Tri-aryl acid derivatives as PPAR receptor ligands |
JP2003530438A (ja) | 2000-04-12 | 2003-10-14 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
AU3947902A (en) | 2000-11-01 | 2002-06-03 | Praecis Pharm Inc | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
JP2004525942A (ja) | 2001-03-29 | 2004-08-26 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
DE60233420D1 (de) | 2001-09-27 | 2009-10-01 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
US6803382B2 (en) | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
KR100451485B1 (ko) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
US20040067266A1 (en) | 2002-10-07 | 2004-04-08 | Toppo Frank R. | Weight loss compound |
US20040157836A1 (en) | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
WO2004078113A2 (en) | 2003-03-04 | 2004-09-16 | Pharmacia Corporation | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents |
US20050239878A1 (en) | 2003-12-29 | 2005-10-27 | Praecis Pharmaceuticals, Inc. | Inhibitors of methionine aminopeptidase-2 and uses thereof |
KR100552043B1 (ko) | 2004-02-28 | 2006-02-20 | 주식회사종근당 | 푸마질롤 유도체를 포함하는 비만치료용 조성물 |
EP1781303A4 (en) | 2004-06-30 | 2008-07-02 | Combinatorx Inc | METHOD AND REAGENTS FOR THE TREATMENT OF METABOLISM DISEASES |
US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
WO2006080591A1 (en) | 2005-01-26 | 2006-08-03 | Chong Kun Dang Pharmaceutical Corp. | Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same |
FR2886855B1 (fr) | 2005-06-08 | 2009-07-17 | Agronomique Inst Nat Rech | Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques |
WO2006138475A2 (en) | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
EP2170402B1 (en) | 2007-06-26 | 2015-03-25 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
NZ585547A (en) | 2007-11-28 | 2012-12-21 | Mersana Therapeutics Inc | Biocompatible biodegradable fumagillin analog conjugates |
EP2317845A4 (en) | 2008-07-18 | 2011-11-09 | Zafgen Inc | METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON |
US8729097B2 (en) | 2008-10-06 | 2014-05-20 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders |
WO2010048499A1 (en) | 2008-10-24 | 2010-04-29 | Wake Forest University | Platinum acridine anti-cancer compounds and methods thereof |
WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
WO2010065881A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
WO2010065879A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
JP5890312B2 (ja) | 2009-10-09 | 2016-03-22 | ザフゲン,インコーポレイテッド | 肥満治療に用いられるスルホン化合物 |
KR101696960B1 (ko) * | 2010-01-08 | 2017-01-16 | 자프겐 인크. | 푸마길롤 타입 화합물 및 그의 제조 및 사용 방법 |
US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
WO2011088055A2 (en) | 2010-01-12 | 2011-07-21 | Zafgen Corporation | Methods and compositions for treating cardiovascular disorders |
US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
US20130210821A1 (en) | 2010-05-27 | 2013-08-15 | James E. Vath | Methods for Treating Obesity |
KR20130043207A (ko) | 2010-07-22 | 2013-04-29 | 자프겐 인크. | 트리시클릭 화합물 및 이의 제조 및 사용 방법 |
AU2011316550A1 (en) | 2010-10-12 | 2013-05-02 | Zafgen, Inc | Sulphonamide compounds and methods of making and using same |
MY177039A (en) | 2010-11-09 | 2020-09-03 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
WO2012064928A1 (en) | 2010-11-10 | 2012-05-18 | Zafgen Corporation | Methods and compositions for treating thyroid hormone related disorders |
US20140011870A1 (en) | 2010-11-29 | 2014-01-09 | Zafgen, Inc. | Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor |
JP2013543899A (ja) | 2010-11-29 | 2013-12-09 | ザフゲン,インコーポレイテッド | 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療 |
US20130316994A1 (en) | 2010-11-29 | 2013-11-28 | Zafgen, Inc. | Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors |
WO2012103333A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen Corporation | Tetrazole compounds and methods of making and using same |
CA2835209A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen, Inc. | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
AU2012253759B2 (en) | 2011-05-06 | 2016-01-21 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
CN103764641B (zh) | 2011-05-06 | 2016-10-26 | 扎夫根股份有限公司 | 部分饱和的三环化合物及其制备和使用方法 |
US9090640B2 (en) | 2011-09-02 | 2015-07-28 | Ulrich Bierbach | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
-
2011
- 2011-11-29 JP JP2013541073A patent/JP2013543899A/ja active Pending
- 2011-11-29 AU AU2011336785A patent/AU2011336785A1/en not_active Abandoned
- 2011-11-29 BR BR112013013411A patent/BR112013013411A2/pt not_active IP Right Cessation
- 2011-11-29 EP EP11794331.6A patent/EP2646016B1/en active Active
- 2011-11-29 WO PCT/US2011/062413 patent/WO2012075020A1/en active Application Filing
- 2011-11-29 CN CN2011800646973A patent/CN103379905A/zh active Pending
- 2011-11-29 MX MX2013005989A patent/MX2013005989A/es active IP Right Grant
- 2011-11-29 CA CA2819251A patent/CA2819251A1/en not_active Abandoned
- 2011-11-29 KR KR1020137016894A patent/KR20140009273A/ko not_active Application Discontinuation
- 2011-11-29 US US13/990,271 patent/US9173865B2/en not_active Expired - Fee Related
-
2013
- 2013-10-17 US US14/056,816 patent/US8980946B2/en not_active Expired - Fee Related
- 2013-10-17 US US14/056,829 patent/US9000035B2/en not_active Expired - Fee Related
-
2015
- 2015-04-02 US US14/677,498 patent/US20150209321A1/en not_active Abandoned
- 2015-09-17 US US14/856,929 patent/US20160243073A1/en not_active Abandoned
-
2017
- 2017-09-13 US US15/703,398 patent/US20180221328A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20140009273A (ko) | 2014-01-22 |
US8980946B2 (en) | 2015-03-17 |
CN103379905A (zh) | 2013-10-30 |
EP2646016A1 (en) | 2013-10-09 |
US20140051752A1 (en) | 2014-02-20 |
AU2011336785A1 (en) | 2013-06-20 |
US9173865B2 (en) | 2015-11-03 |
US20140045934A1 (en) | 2014-02-13 |
EP2646016B1 (en) | 2017-05-17 |
US20140045935A1 (en) | 2014-02-13 |
BR112013013411A2 (pt) | 2016-09-13 |
US9000035B2 (en) | 2015-04-07 |
JP2013543899A (ja) | 2013-12-09 |
US20160243073A1 (en) | 2016-08-25 |
US20150209321A1 (en) | 2015-07-30 |
WO2012075020A1 (en) | 2012-06-07 |
US20180221328A1 (en) | 2018-08-09 |
CA2819251A1 (en) | 2012-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013005989A (es) | Tratamiento de obesidad utilizando administracion no diaria de 6-o-(4-dimetilaminoetoxi)cinamoil fumagilol. | |
NZ590732A (en) | Methods of treating an overweight or obese subject using fumagillin | |
WO2012012695A3 (en) | A method for the treatment of obesity | |
MX2012003612A (es) | Bifidobacterium longum atcc baa-99 (bl999) y control de peso. | |
IL195616A0 (en) | Membrane augmentation, such as of for treatment of cardiac valves, and fastening devices for membrane augmentation | |
WO2010065877A9 (en) | Methods of treating an overweight or obese subject | |
WO2010065879A9 (en) | Methods of treating an overweight or obese subject | |
GEP20156329B (en) | CHEMICAL MODIFICATIONS OF miRNA INHIBITORS AND MIMETICS | |
EP2414032A4 (en) | FEEDBACK SYSTEMS AND METHOD FOR TRANSMITTING DIAGNOSIS AND / OR TREATMENT SIGNALS FOR IMPROVING THE TREATMENT OF ADIPOSITAS | |
EP2194917A4 (en) | DEVICES AND METHODS FOR THE TREATMENT OF OBESITY | |
WO2008030505A3 (en) | Methods and compositions for the treatment of antibody mediated neuropathies | |
BR112014028041A2 (pt) | tratamento de obesidade hipotalâmica com inibidores de metap2 | |
ZA201101814B (en) | Prevention, treatment and diagnosis of p.gingivalis infection | |
WO2012051567A8 (en) | Obesity-related genes and their proteins and uses thereof | |
GEP20156226B (en) | Compositions for treating centrally mediated nausea and vomiting | |
IN2012DN02624A (es) | ||
MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
WO2010132622A3 (en) | Anticd20-cpg conjugates and methods of treating b cell malignancies | |
EA201200428A1 (ru) | Композиция и способ для лечения ожирения | |
EP2533635A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ADIPOSITAS AND ADIPOSITASIS | |
WO2011130692A3 (en) | Androgen induced oxidative stress inhibitors | |
EP2608794A4 (en) | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF OBESITY | |
IN2014MN01407A (es) | ||
WO2011017488A3 (en) | Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity | |
WO2011110367A3 (en) | Method of screening for htra protease inhibitors useful for prophylaxis and therapy of a bacterial infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |